Brief: Neurizon's NUZ-001 Reduces Aggregation Of Key ALS Disease Target TDP-43 In Preclinical Study
19/11/2024 10:41
Nov 19 (Reuters) - Neurizon Therapeutics Ltd NUZ.AX :
* NEURIZON'S NUZ-001 REDUCES AGGREGATION OF KEY ALS DISEASE
TARGET
TDP-43 IN PRECLINICAL STUDY
Source text: ID:nPreDpYn6a
Further company coverage: NUZ.AX
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Neurizon Therapeutics
See all newsAustralia's Neurizon Therapeutics jumps on deal with US firm
Brief: Neurizon Therapeutics Executes Long-Term Supply Agreement With Elanco
Brief: Neurizon Therapeutics Receives Ethics Approval For Phase 1 Nuz-001 Oral Liquid Formulation Study
Brief: Neurizon Therapeutics Announces Placement Of Entitlement Offer Shortfall To Raise ~A$2.7 Million
Brief: Neurizon Therapeutics Says Michael Thurn Resigns As Managing Director And CEO